GET THE APP

Vitrectomy for proliferative diabetic retinopathy, is it enough? | 52395
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

+44 1223 790975

Vitrectomy for proliferative diabetic retinopathy, is it enough?


5th International Conference on Clinical & Experimental Ophthalmology

August 04-06, 2015 Valencia, Spain

Rohit Sanjay Laul, Atif Ali Mir, Amar Agarwal and Shazia Shafi

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Purpose: To find out the effectiveness of vitrectomy with intraoperative bevacizumab injection in pseudophakic patients with
proliferative diabetic retinopathy.
Material & Method: A total of 45 pseudophakic eyes of 45 patients with proliferative diabetic retinopathy underwent standard
23G Pars Plana with intraoperative bevacizumab injection and were followed up for 6 months. Patients age ranged from 46-83
years of which 30(66.66%) were males and 15(33.34%) were females. After detailed history taking, they underwent assessment
of visual acuity, slit lamp biomicroscopy, fundus examination using 78D lens, indirect ophthalmoscope with 20D lens & B-scan.
Standard 23 G pars plana vitrectomy with intraoperative bevacizumab injection was performed in all the cases. Follow up
examination was done on next day, at 15 days, 3 months and 6 months following the surgery. The visual acuity, recurrence of
hemorrhage and need for another vitrectomy were analysed.
Results: The visual acuity improved in 34 eyes (75.55%), after vitrectomy with intraoperative bevacizumab injection. The mean
postoperative visual acuity was significantly better than mean preoperative visual acuity. Recurrence of hemorrhage was noted
in 4 eyes (8.88%) out of which only 1 eye (2.22%) required another vitrectomy for clearance of hemorrhage.
Conclusion: These results demonstrates that vitrectomy with intraoperative bevacizumab injection is an effective procedure
in, treating proliferative diabetic retinopathy in pseudophakic patients, reducing the recurrence of hemorrhage and need for
another vitrectomy.

Biography :

Rohit Sanjay Laul has completed his MBBS and MS Ophthalmology from Maharashtra University of Health Sciences, Nashik, India in 2008 and 2013 respectively. Then
he joined as long term Vitreoretina fellow at Dr. Agarwal’s Retina Foundation, Chennai, India where he underwent rigorous training in medical and surgical management of
vitreoretinal diseases. He passed optics & refraction, basic sciences and clinical sciences examinations conducted by International Council of Ophthalmology UK. He has
presented several posters in state conferences and has publications to his name in the International Journal of Medical Research. He is now working under Dr. Atif Ali Mir,
Senior Vitreoretinal Surgeon & Director Retina services of all Dr. Agarwal’s Eye Hospitals in the golden quadrilateral of Tamil Nadu. The area of his interest is management
of advanced diabetic eye diseases, macular diseases and age related macular degeneration.

Top